Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

NCT00606580 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

375

Enrollment

FED

Sponsor class

Conditions

Cutaneous Leishmaniasis

Interventions

DRUG: WR 279,396 topical cream
DRUG: Paromomycin Alone topical cream
DRUG: Vehicle placebo cream

Sponsor

U.S. Army Medical Research and Development Command